Clinical Trial Update: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin (SGN-35) as salvage treatment for CD30-positive germ cell tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Cancer

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Fondazione Michelangelo | Conditions: Germ Cell Cancer | Phase 2 | Status: COMPLETED